2008-07-02 20:07:16 - www.companiesandmarkets.com adds new report - Premium Company Profile - OSI Pharmaceuticals

www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction

OSI Pharmaceuticals´ (OSI Pharma) main focus is to discover and develop novel drugs and build innovative commercialized molecular targeted therapies. The company has three marketed products, namely, Tarceva, Novantrone and Macugen for various indications in the areas of oncology, ophthalmology and diabetes.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products

and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

OSI Pharma is a research-driven biotechnology company, engaged in the discovery and development of novel drugs and building innovative commercialized molecular targeted therapies.The company markets three products: Tarceva, Novantrone and Macugen. Tarceva.



OSI Pharma´s major revenue contributor, is a small molecule designed to target the human epidermal growth factor receptor (HER1) pathway, also known as EGFR, which is critical to cell growth in many cancers, indicated for the treatment of advanced non-small cell lung cancer and pancreatic cancer.



OSI Pharma derives its revenues from marketing of pharmaceutical products and from royalties, license and collaborative agreements consisting payments related to the commercialization of its products in other countries with other pharmaceutical companies.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization